COVID-19 mRNA疫苗对退伍军人COVID-19相关住院的有效性
CDC评估了mRNA疫苗在五个退伍军人医疗中心对COVID-19相关住院的有效性,纳入1175名住院退伍军人。调整后疫苗有效性为86.8%(95%CI 80.4%-91.1%),Delta变异株流行前后相似。65岁及以上成人有效性79.8%,18-64岁为95.1%。
要点
- mRNA疫苗对退伍军人COVID-19相关住院的调整后有效性为86.8%。
- Delta变异株流行前后疫苗有效性相似(84.1% vs 89.3%)。
- 65岁及以上成人疫苗有效性较低(79.8%),18-64岁较高(95.1%)。
核心结论
- COVID-19 mRNA疫苗在年老、种族多样且以男性为主的美国退伍军人群体中能高度有效预防COVID-19相关住院。
研究设计与样本
- CDC评估了2021年2月1日至8月6日在五个退伍军人医疗中心住院的1175名18岁及以上美国退伍军人中mRNA疫苗对COVID-19相关住院的有效性。
主要发现
- 住院者中1093人(93.0%)为男性,中位年龄68岁,574人(48.9%)为非西班牙裔黑人,522人(44.4%)Charlson合并症指数评分≥3。
- 总体调整后疫苗有效性为86.8%(95%CI 80.4%-91.1%)。
- Delta变异株流行前(2月1日-6月30日)和流行期间(7月1日-8月6日)疫苗有效性分别为84.1%和89.3%。
- 65岁及以上成人疫苗有效性为79.8%(95%CI 67.7%-87.4%),18-64岁为95.1%(95%CI 89.1%-97.8%)。
临床怎么用
- 为预防COVID-19相关住院,所有符合条件者均应接种COVID-19疫苗。
局限性
- 需要对不同年龄组的疫苗有效性进行进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) have been shown to be highly protective against COVID-19-associated hospitalizations (1-3). Data are limited on the level of protection against hospitalization among disproportionately affected populations in the United States, particularly during periods in which the B.1.617.2 (Delta) variant of SARS-CoV-2, the virus that causes COVID-19, predominates (2). U.S. veterans are older, more racially diverse, and have higher prevalences of underlying medical conditions than persons in the general U.S. population (2,4). CDC assessed the effectiveness of mRNA vaccines against COVID-19-associated hospitalization among 1,175 U.S. veterans aged ≥18 years hospitalized at five Veterans Affairs Medical Centers (VAMCs) during February 1-August 6, 2021. Among these hospitalized persons, 1,093 (93.0%) were men, the median age was 68 years, 574 (48.9%) were non-Hispanic Black (Black), 475 were non-Hispanic White (White), and 522 (44.4%) had a Charlson comorbidity index score of ≥3 (5). Overall adjusted vaccine effectiveness against COVID-19-associated hospitalization was 86.8% (95% confidence interval [CI] = 80.4%-91.1%) and was similar before (February 1-June 30) and during (July 1-August 6) SARS-CoV-2 Delta variant predominance (84.1% versus 89.3%, respectively). Vaccine effectiveness was 79.8% (95% CI = 67.7%-87.4%) among adults aged ≥65 years and 95.1% (95% CI = 89.1%-97.8%) among those aged 18-64 years. COVID-19 mRNA vaccines are highly effective in preventing COVID-19-associated hospitalization in this older, racially diverse population of predominately male U.S. veterans. Additional evaluations of vaccine effectiveness among various age groups are warranted. To prevent COVID-19-related hospitalizations, all eligible persons should receive COVID-19 vaccination.
引用
- Bajema KL, Dahl RM, Prill MM, et al. Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalization - Five Veterans Affairs Medical Centers, United States, February 1-August 6, 2021. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34529636. doi:10.15585/mmwr.mm7037e3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。